Abstract
Survival of patients with chronic myeloid leukemia (CML) has improved with the use of imatinib and other tyrosine kinase inhibitors. There is limited data on second primary malignancies (SPM) in CML. We analyzed the SPMs rates among CML patients reported to Surveillance, Epidemiology, and End Results (SEER) database during pre-(1992–2000) and post-(2002–2009) era. We used SEER Multiple Primary-Standardized Incidence Ratio session to calculate standardized incidence ratios (SIRs). Among 8,511 adult CML patients, 446 patients developed 473 SPMs. The SIR for SPMs in CML patients was significantly higher with observed/expected ratio:1.27, P < 0.05 and absolute excess risk of 32.09 per 10,000 person years compared to general population. The rate of SPMs for cancers of all sites in post-imatinib era were significantly higher compared to pre-imatinib era with observed/expected ratio of 1.48 versus 1.06, P = 0.03. This study showed that risk of SPMs is higher among CML patients. The risk of SPMs is significantly higher in post-imatinib era compared to pre-imatinib era.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348(11):994–1004
Seggewiss R, Loré K, Greiner E, Magnusson MK, Price DA, Douek DC et al (2005) Imatinib inhibits T-cell receptor–mediated T-cell proliferation and activation in a dose-dependent manner. Blood 105:2473–2479
Penn I, Starzl TE (1973) Immunosuppression and cancer. Transplant Proc 5(1):943–947
http://www.pharma.us.novartis.com/product/pi/pdf/gleevec_tabs.pdf. Accessed 21 Sept 2013
http://seer.cancer.gov/about/factsheets/SEER_Research_Brochure.pdf. Accessed 21 Sept 2013
Mandal R, Bolt DM, Shah BK (2013) Disparities in chronic myeloid leukemia survival by age, gender, and ethnicity in pre- and post-imatinib eras in the US. Acta Oncol 52(4):837–841
Miranda MB, Lauseker M, Proetel U, Schreiber A, Hanfstein B, Baerlocher GM, et al. Secondary malignancies in CML patients—data from the german CML study IV. 54th ASH Annual Meeting and Exposition; 8–11 December 2012. Abstr 3746
Imatinib prescribing information. Novartis Pharmaceuticals. 2010. http://www.pharma.us.novartis.com/product/pi/pdf/gleevec_tabs.pdf. Accessed 21 Sept 2013
Verma D, Kantarjian H, Strom SS, Rios MB, Jabbour E, Quintas-Cardama A et al (2011) Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood 118(16):4353–4358
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shah, B.K., Ghimire, K.B. Second Primary Malignancies in Chronic Myeloid Leukemia. Indian J Hematol Blood Transfus 30, 236–240 (2014). https://doi.org/10.1007/s12288-013-0328-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12288-013-0328-2